Mobile App

Google Play Apple Store
Pulmonary Arterial Hypertension in Special Populations
Certified CME/CNE Activity - Mini Modules
While PH/PAH is a collection of diseases and conditions with diverse etiologies, the majority of clinical trial data has featured a narrow spectrum of illness. Extrapolating clinical trial data from one population to another group has not been proven to demonstrate similar levels of efficacy or safety. Additionally, within the “traditional” PAH population, the subgroup of males with IPAH/APAH have consistently showed a more-rapid course of illness than females.

These educational Mini Modules will outline the issue of the gender paradox, as well as diagnostic and treatment issues relating to PAH related to liver disease (portopulmonary hypertension), PAH related to drugs and toxins, out-of-proportion PAH associated with chronic obstructive pulmonary disease (COPD), and patients with Group 1 PAH, which includes pulmonary vaso-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH).
Review one (or all) Mini Modules of interest. Claim AMA or ANCC credit/contact hour(s) per module after completion of each brief Post-Test/Evaluation.
Harrison W. Farber
Harrison W. Farber, MD
Professor of Medicine
Boston University School of Medicine
Director, Pulmonary Hypertension Center
Boston Medical Center



20
Supported by an independent educational grant from Gilead Sciences Medical Affairs and United Therapeutics Corporation
Expired Activity
Mini Module
6156
Pulmonology